Effect of rosiglitazone on cardiac fibroblast proliferation, nitric oxide production and connective tissue growth factor expression induced by advanced glycation end-products

Journal of International Medical Research

Volumn 36, Issue 2, 2008, Pages 329-335

  Li, J ^a   Liu, Nai Feng ^b   Wei, Q ^b  

^a SOUTHEAST UNIVERSITY   (China)

^b AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Cardic fibroblasts; Connective tissue growth factor; Nitric oxide; Rosiglitazone

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADVANCED GLYCATION END PRODUCT; CONNECTIVE TISSUE GROWTH FACTOR; NITRATE REDUCTASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ASSAY; FIBROBLAST CULTURE; FLOW CYTOMETRY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; INCUBATION TIME; INHIBITION KINETICS; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

EID: 42049112158     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600216     Document Type: Article

References (14)

1. Brownlee M: Glycosylation products as toxic mediators of diabetic complications. Annu Rev Med 1991; 42: 159-166.
2. Way KJ, Isshiki K, Suzuma K, et al: Expression of connective growth factor is increased in injured myocardium associated with protein kinase C P2 activation and diabetes. Diabetes 2002; 51: 2709-2718.
3. Uchimura K, Nakamuta M, Enjoji M, et al: Activation of retinoic X receptor and peroxisome proliferator-activated receptor-γ inhibits nitric oxide and tumor necrosis factor-α production in rat Kupffer cells. Hepatology 2001; 33: 91-99.
4. Wong A, Dukic-Stefanovic S, Gusic-Milenkovic J, et al: Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. Eur J Neurosci 2001; 14: 1961-1967.
5. Xu B, Chibber R, Ruggiero D, et al: Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17: 1289-1291.
6. He Y, Huang Y, Zhou L, et al: All-trans retinoic acid inhibited angiotensin II-induced increase in cell growth and collogen secretion of neonatal cardiac fibroblasts. Acta Pharmacol Sin 2006; 27: 423-429.
7. Sun K, Wang Q, Huang XH: PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective growth factor expression. Acta Pharmacol Sin 2006; 27: 715-723.
8. Cooper ME: Importance of advanced glycation end products in diabetes-associated cardiovascular and renal diseases. Am J Hypertens 2004; 17: 31S-38S.
9. Passeri J, Bloch KD: Nitric oxide and cardiac remodeling. Heart Fail Clin 2005; 1: 275-286.
10. Chang PC, Chen TH, Chang CJ, et al: Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via p38 MAPK-dependent pathway. Kidney Int 2004; 65: 1664-1675.
11. Crosby MB, Svenson J, Gilkeson GS, et al: A novel PPAR response element in the murine iNOS promoter. Mol Immunol 2005; 42: 1303-1310.
12. 2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 2000; 49: 346-355.
13. Cernuda-Morollon E, Rodriguez-Pascual F, Klatt P, et al: PPAR agonists amplify iNOS expression while inhibiting NF-kappaB: implications for mesangial cell activation by cytokines. J Am Soc Nephrol 2002; 13: 2223-2231.
14. Sorrentino SA, Bahlmann FH, Besler C, et al: Impaired in vivo reendothelialization capacity of endothelial progenitor cells of patients with type-2 diabetes is restored by PPAR-gamma agonist rosiglitazone: role of NAD(P)H oxygenase and nitric oxide. Vasc Pharmacol 2006; 45: e27-e28.